Articles

P4.11 Unusual cutaneous paraneoplastic syndrome in the setting of acute myeloid leukemia

BJH - volume 7, issue Abstract Book BHS, january 2016

T. Tamakloe , N. Meité , S. Amat , P. Janssens , L. Marot , J-P. Defour PhD, P. Saussoy MD, PhD, H. Poirel , L. Michaux MD, PhD, E. Van den Neste MD, PhD, L. Knoops MD, PhD, V. Havelange MD, PhD, C. Lambert MD, X. Poiré MD, M-C. Vekemans MD

Read more

Diagnosis and treatment of AL Amyloidosis in 2015: Consensus guidelines of the Belgian Hematological Society

BJH - volume 6, issue 5, december 2015

K. Beel MD, PhD, M-C. Vekemans MD, G. Bries MD, PhD, J. Caers MD, PhD, B. De Pryck MD, K. Fostier MD, A. Kentos MD, N. Meuleman MD, PhD, P. Mineur MD, I. Van de Broek MD, PhD, K.L. Wu MD, PhD, C. Doyen MD, PhD, M. Delforge MD, PhD

Summary

Immunoglobulin light chain amyloidosis is a clonal plasma cell dyscrasia, historically associated with a very poor prognosis. Prompt diagnosis is critical to preserve organ function and improve survival in immunoglobulin light chain amyloidosis patients. The severity of cardiac involvement and response to treatment are the most important prognostic factors. Serum free light chain ratio and cardiac biomarkers troponin T and N-terminal pro-brain natriuretic peptide are powerful tools for the evaluation of prognosis and treatment response. Historically, treatment with autologous stem cell transplantation appears to offer a survival benefit, but is only an option in a minority of patients. IMiDs, and especially proteasome inhibitors, have shown promising activity in immunoglobulin light chain amyloidosis. Supportive care should be integrated in the treatment plan and requires a multidisciplinary approach. These guidelines summarise a consensus of the myeloma subcommittee of the Belgian Hematological Society on diagnosis, cytoreductive and supportive treatment of immunoglobulin light chain amyloidosis, based on an extended review of the literature. Where applicable, comments were added with respect to the Belgian reimbursement modalities.

(BELG J HEMATOL 2015;6(5):187–94)

Read more

P1.07 Unusual progression of a B-cell non-Hodgkin’s lymphoma

BJH - volume 6, issue Abstract Book BHS, january 2015

E. Collinge , A. vanden Daelen , L. Marot , A. Camboni MD, PhD, J-P. Defour PhD, P. Saussoy MD, PhD, L. Michaux MD, PhD, M-C. Vekemans MD, L. Knoops MD, PhD

Read more

P1.15 Outcome after salvage chemotherapy with DHAP/ICE-type regimens and attempt to transplant in patients with aggressive lymphoma: experience of a single centre

BJH - volume 6, issue Abstract Book BHS, january 2015

P.D.M. Katoto , N. Vanlangendonck , V. Havelange MD, PhD, X. Poiré MD, C. Lambert MD, M-C. Vekemans MD, A. Ferrant , V. Lannoy , E. Van den Neste MD, PhD

Read more

P3.15 Clofarabine as salvage therapy and bridge to transplantation in acute leukemia. A single center experience

BJH - volume 6, issue Abstract Book BHS, january 2015

G. Di Prinzio , C. Cornil , E. Collinge , A. Devresse , P.D.M. Katoto , V. Havelange MD, PhD, E. Van den Neste MD, PhD, X. Poiré MD, M-C. Vekemans MD

Read more

P4.06 A pernicious anemia hiding under the guise of a normocytic anemia

BJH - volume 6, issue Abstract Book BHS, january 2015

A. Dermine , J. Dewulf , J-P. Defour PhD, M-C. Vekemans MD

Read more

P1.06 Bilateral Bell’s palsy leading to the diagnosis of chronic lymphocytic leukemia

BJH - volume 6, issue Abstract Book BHS, january 2015

C. Cornil , E. Collinge , G. Di Prinzio , A. Devresse , J-P. Defour PhD, P. Saussoy MD, PhD, L. Michaux MD, PhD, L. Knoops MD, PhD, M-C. Vekemans MD, A. Ferrant

Read more